This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Oncolytic Viruses / Non-viral Gene Therapy Delivery
November 30 - December 1, 2022
Digital Conference8:00AM EST // 1:00PM GMT // 2:00PM CET

Richard Vile
Consultant, Department of Molecular Medicine at Mayo Clinic, USA


My primary research interests are centered on the development of gene-, viro-, adoptive T cell and immuno-therapies for cancer (Nat Med. 2011 Jun 19;17(7):854-9. PMID: 21685898; Nat Commun. 2020 Jun 24;11(1):3187. PMID: 32581235; Nat Commun. 2021 Mar 26;12(1):1930. PMID: 33772027; Science. 2021 Dec 10;374(6573):1325-1326. PMID: 34882456). We use murine and human models to test strategies by which oncolytic viruses can be delivered systemically to metastatic disease and how oncolytic viroimmunotherapy can be combined with adoptive T cell therapy, such as with CAR T cells, to improve the efficacy of either alone. In addition, we have a long term interest in defining how the immune system can be re-educated to recognize and react against tumor associated antigens. Our pre-clinical studies are focused on translational relevance and we are developing improved immunotherapies for pediatric brain tumors. In the past three years, we have received NIH RO1, PO1 and R21 funding, a Hyundai Hope on Wheels award for the development of novel pediatric glioma therapies and we have collaborative projects with several Biotech companies to take oncolytic viruses to the clinic. I am currently the PI, or co-PI, on three different clinical trials in collaboration with our clinical partners in London and Leeds in the UK,. I have mentored 25 PhD and MD-PhD students over the past 10 years.

Agenda Sessions

  • Targeting Solid Tumors Using Oncolytic Virus and CAR T Cell Combined Therapy